Pratibha S. Binder

Pratibha S. Binder

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EWElise Marie Wilson
Elise Marie Wilson
RERamez N. Eskander
Ramez N. Eskander
PBPratibha S. Binder
Pratibha S. Binder
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors mutate and progress through traditional lines of treatment, new therapies must be developed to overcome resistance and target cancer-specific receptors and mutations. Recent advances in the development of immunotherapy and antibody–drug conjugates have resulted in compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers. In the last decade, several immunotherapy agents have received FDA approval or NCCN guideline recommendation for the treatment of gynecologic malignancies, including dostarlimab for advanced or recurrent endometrial cancer and pembrolizumab for advanced or recurrent cervical and endometrial cancers. Several other immunotherapeutic agents are under active investigation. Development of antibody–drug conjugates including tisotumab vedotin in cervical cancer, mirvetuximab soravtansine in ovarian cancer, and trastuzumab deruxtecan in multiple gynecologic cancers has translated into exciting efficacy signals, prompting full drug approvals and additional investigation. This article aims to review recent novel advances in targeted treatments for gynecologic malignancies, highlighting the trials and data underlying these novel interventions.

1 October 2021 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
DMDora J. Melber
Dora J. Melber
ZBZachary T Berman
Zachary T Berman
MJMarni B. Jacobs
Marni B. Jacobs
APAndrew C. Picel
Andrew C. Picel
CCCharlotte L. Conturie
Charlotte L. Conturie
TKThomas F. Kelly
Thomas F. Kelly
Multidisciplinary care of placenta accreta spectrum cases improves pregnancy outcomes, but the specific components of such a multidisciplinary collaboration varies between institutions. As experience with placenta accreta spectrum increases, it is crucial to assess new surgical techniques and protocols to help improve maternal outcomes and to advocate for hospital resources. This study aimed to assess a novel multidisciplinary protocol for the treatment of placenta accreta spectrum that comprises cesarean delivery, multivessel uterine embolization, and hysterectomy in a single procedure within a hybrid operative suite. This was a matched prepost study of placenta accreta spectrum cases managed before (2010-2017) and after implementation of the Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization protocol (2018-2021) at a tertiary medical center. Historical cases were managed with internal iliac artery balloon placement in selected cases with the decision to inflate the balloons intraoperatively at the discretion of the primary surgeon. Intraoperative Embolization cases were compared with historical cases in a 1:2 ratio matched on the basis of placenta accreta spectrum severity and surgical urgency. The primary outcome was a requirement for transfusion with packed red blood cells. Secondary outcomes included estimated surgical blood loss, operative and postoperative complications, procedural time, length of stay, and neonatal outcomes. A total of 15 Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization cases and 30 matched historical cases were included in the analysis. There were no demographic differences noted between the groups. A median (interquartile range) of 0 units (0-2 units) of packed red blood cells were transfused in the Intraoperative Embolization group compared with 2 units (0-4.5 units) in the historical group (P=.045); 5 of 15 (33.3%) Intraoperative Embolization cases required blood transfusions compared with 19 of 30 (63.3%) cases in the historical group (P=.11). The estimated blood loss was significantly less in the Intraoperative Embolization group with a median (interquartile range) of 750 mL (450-1050 mL) compared with 1750 mL (1050-2500 mL) in the historical group (P=.003). There were no cases requiring massive transfusion (≥10 red blood cell units in 24 hours) in the Intraoperative Embolization group compared with 5 of 30 (16.7%) cases in the historical group (P=.15). There were no intraoperative deaths from hemorrhagic shock using the Intraoperative Embolization protocol, whereas this occurred in 2 of the historical cases. The mean duration of the interventional radiology procedure was longer in the Intraoperative Embolization group (67.8 vs 34.1 minutes; P=.002). Intensive care unit admission and postpartum length of stay were similar, and surgical and postoperative complications were not significantly different between the groups. The gestational age and neonatal birthweights were similar; however, the neonatal length of stay was longer in the Intraoperative Embolization group (median duration, 32 days vs 15 days; P=.02) with a trend toward low Apgar scores. Incidence of arterial umbilical cord blood pH <7.2 and respiratory distress syndrome and intubation rates were not statistically different between the groups. A multidisciplinary pathway including a single-surgery protocol with multivessel uterine embolization is associated with a decrease in blood transfusion requirements and estimated blood loss with no increase in operative complications. The Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization protocol provides a definitive surgical method that warrants consideration by other centers specializing in placenta accreta spectrum treatment.

14 December 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
BMBrennan Marsh-Armstrong
Brennan Marsh-Armstrong
JVJula Veerapong
Jula Veerapong
MTMichael Taddonio
Michael Taddonio
SBSarah Boles
Sarah Boles
JSJason Keith Sicklick
Jason Keith Sicklick
PBPratibha S. Binder
Pratibha S. Binder
• Desmoid fibromatoses grow rapidly during the high estrogen-state of pregnancy. • Mass effect on the bladder is a complication of abdominal desmoid fibromatoses. • Cryoablation, doxorubicin, and post-partum prolactin are fetal-protective treatments. • Desmoid tumors can be effectively treated with fetal-protective strategies.

12 March 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PBPratibha S. Binder
Pratibha S. Binder
YHYassar M. Hashim
Yassar M. Hashim
JCJames Cripe
James Cripe
TBTommy Buchanan
Tommy Buchanan
AZAbigail Zamorano
Abigail Zamorano
DSDirk Spitzer
Dirk Spitzer
Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve more durable treatment responses by combining cisplatin chemotherapy with SW IV-134, a cancer-targeted peptide mimetic and inducer of cell death. SW IV-134 is a recently developed small molecule conjugate linking a sigma-2 ligand with a peptide analog (mimetic) of the intrinsic death pathway activator SMAC (second-mitochondria activator of caspases). The sigma-2 receptor is overexpressed in ovarian cancer and the sigma-2 ligand portion of the conjugate facilitates cancer selectivity. The effector portion of the conjugate is expected to synergize with cisplatin chemotherapy and the cancer selectivity is expected to reduce putative off-target toxicities. Ovarian cancer cell lines were treated with cisplatin alone, SW IV-134 alone and a combination of the two drugs. Treatment efficacy was determined using luminescent cell viability assays. Caspase-3/7, − 8 and − 9 activities were measured as complementary indicators of death pathway activation. Syngeneic mouse models and patient-derived xenograft (PDX) models of human ovarian cancer were studied for response to SW IV-134 and cisplatin monotherapy as well as combination therapy. Efficacy of the therapy was measured by tumor growth rate and survival as the primary readouts. Potential drug related toxicities were assessed at necropsy. The combination treatment was consistently superior in multiple cell lines when compared to the single agents in vitro. The expected mechanism of tumor cell death, such as caspase activation, was confirmed using luminescent and flow cytometry-based assay systems. Combination therapy proved to be superior in both syngeneic and PDX-based murine models of ovarian cancer. Most notably, combination therapy resulted in a complete resolution of established tumors in all study animals in a patient-derived xenograft model of ovarian cancer. The addition of SW IV-134 in combination with cisplatin chemotherapy represents a promising treatment option that warrants further pre-clinical development and evaluation as a therapy for women with advanced ovarian cancer.

1 May 2026 in Current Women s Health Reviews
Verified
Journal Article
Closed access
PDF file
KKKelsey J. Keverline
Kelsey J. Keverline
ABAllison L. Brodsky
Allison L. Brodsky
APArchita Pemmaraju
Archita Pemmaraju
OMOmar Mesina
Omar Mesina
SPSteven Plaxe
Steven Plaxe
PBPratibha S. Binder
Pratibha S. Binder
Introduction: This study aimed to quantify narcotic waste associated with patientcontrolled analgesia during the immediate post-operative period following gynecologic oncology surgery. Methods: We identified women who underwent abdominal surgery with a gynecologic oncologist at a single institution and reviewed their medical records retrospectively. The information on demographics, surgery, pathology, pain control methods, and narcotic use was collected. Narcotic waste is defined as narcotics that are opened, not used, and cannot be recycled. Statistical analysis included medians, frequencies, Mann-Whitney U tests, and Kruskal-Wallis tests with a set p-value of <0.05. Results: A total of 494 surgeries performed between 2019 and 2021 were reviewed, of which 100 (20.2%) patients received patient-controlled analgesia with hydromorphone post-operatively. The median waste for patient-controlled analgesia was 61% of the medication prepared. There was no statistically significant difference in patient-controlled analgesia waste when controlling for preoperative medications or regional blocks (p = 0.5). When surgeries were further categorized based on complexity, no significant difference in post-operative narcotic waste was identified (p=0.07). Sixty percent of patient-controlled analgesia pumps were discontinued on the first postoperative day. Six percent of patients did not use the patient-controlled analgesia at all (100% waste). Discussion: Clinically significant narcotic waste was identified post-operatively in gynecologic oncology patients who received a hydromorphone patient-controlled analgesia pump. Conclusion: Surgeons and anesthesiologists may consider focusing on multimodal pain regimens, reducing patient-controlled analgesia use, and prescribing narcotics on demand and when indicated.

9 September 2022 in Gynecologic Oncology
Verified
Journal Article
Closed access
AHAnjali Hari
Anjali Hari
KFKatelyn Furey
Katelyn Furey
JJJessica Jou
Jessica Jou
SASophia Angelides
Sophia Angelides
FAFaaizah Arshad
Faaizah Arshad
JCJoshua Cohen
Joshua Cohen